Want to see TVGN full AI Analyst Report?
TVGN Stock Chart & Stats
$6.81
$0.08(1.81%)
At close: 4:00 PM EDT
$6.81
$0.08(1.81%)
Day’s Range― - ―
52-Week Range$3.64 - $39.04
Previous CloseN/A
Volume8.49K
Average Volume (3M)7.58K
Market Cap
$43.49M
Enterprise Value$38.83M
Total Cash (Recent Filing)$1.08M
Total Debt (Recent Filing)$3.04M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.83
Shares Outstanding6,511,540
10 Day Avg. Volume6,806
30 Day Avg. Volume7,585
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-189.46
Enterprise Value/Ebitda-1.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lower DebtThe substantial reduction in debt improves the company’s leverage profile and reduces fixed financing pressure compared with earlier periods. This gives management more flexibility to direct future capital toward clinical translation, platform development, and potential commercialization rather than debt service.
Narrower LossesAlthough Tevogen remains unprofitable, the reported loss level improved meaningfully versus 2023. If this direction reflects tighter spending or better operating discipline, it could moderate the resources required to advance the pipeline and extend the company’s ability to pursue development milestones.
Nasdaq ComplianceRegaining full Nasdaq compliance removes previously disclosed listing issues and supports continued access to a major public-market platform. That stability can help preserve stakeholder confidence and maintain financing and strategic flexibility while the company pursues its healthcare and technology strategy.
Bears Say
Pre-Revenue ModelZero reported revenue indicates Tevogen is still pre-commercial and has not yet demonstrated product-sales traction. Its biotechnology strategy therefore depends on successful clinical translation and eventual commercialization, leaving near-term financial performance disconnected from operating revenue.
Persistent Cash BurnSustained negative operating and free cash flow means the business consumes cash to fund ongoing operations rather than generating internal funding. Unless revenue develops or spending declines, continued development will require external capital, increasing financial execution pressure over the next several quarters.
Negative EquityA negative equity base signals limited balance-sheet cushion and weak financial resilience if losses continue. It also raises the likelihood that future funding may be needed to support operations, with financing potentially constraining strategic flexibility and creating dilution risk for existing shareholders.
Tevogen Bio Holdings News
TVGN FAQ
What was Tevogen Bio Holdings’s price range in the past 12 months?
Tevogen Bio Holdings lowest stock price was $3.64 and its highest was $39.04 in the past 12 months.
What is Tevogen Bio Holdings’s market cap?
Tevogen Bio Holdings’s market cap is $43.49M.
When is Tevogen Bio Holdings’s upcoming earnings report date?
Tevogen Bio Holdings’s upcoming earnings report date is Nov 24, 2026 which is in 41 days.
How were Tevogen Bio Holdings’s earnings last quarter?
Tevogen Bio Holdings released its earnings results on Aug 13, 2026. The company reported -$1.525 earnings per share for the quarter.
Is Tevogen Bio Holdings overvalued?
According to Wall Street analysts Tevogen Bio Holdings’s price is currently Overvalued.
Does Tevogen Bio Holdings pay dividends?
Tevogen Bio Holdings does not currently pay dividends.
What is Tevogen Bio Holdings’s EPS estimate?
Tevogen Bio Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tevogen Bio Holdings have?
Tevogen Bio Holdings has 6,511,540 shares outstanding.
What happened to Tevogen Bio Holdings’s price movement after its last earnings report?
Tevogen Bio Holdings reported an EPS of -$1.525 in its last earnings report. Following the earnings report the stock price went up 1.546%.
Which hedge fund is a major shareholder of Tevogen Bio Holdings?
Currently, no hedge funds are holding shares in TVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tevogen Bio Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.32%
12-Months-Change
Fundamentals
Return on Equity
248.50%
Trailing 12-Months
Asset Growth
10.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tevogen Bio Holdings
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
Technical Analysis
Nkarta
―
C4 Therapeutics
―
Shattuck Labs
―
Nuvectis Pharma
―
Actuate Therapeutics, Inc.
―
Ownership Overview
71.78% Insiders
0.71% Mutual Funds
<0.01% Other Institutional Investors
27.25% Public Companies and
Individual Investors